share_log

Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US

Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US

分析師認為CRISPR Treateutics的鐮刀細胞候選在美國的時間表有所緩和
Benzinga Real-time News ·  2022/08/09 15:28
  • Barclays says that CRISPR Therapeutics AG's (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the goal of on-track regulatory submissions for CTX001 in SCD/BT by YE22 and CTA submission for VCTX211 (next generation) for Type 1 Diabetes (T1D) in 2H22. 
  • Though investors are focused on BLA submission for CTX001, the analyst expects a high probability of approval even with some delay. 
  • But Barclays has moved to the sidelines, given some questions on the durability of the allogeneic CAR-T programs and the lack of other major data catalysts in the next 12 months. 
  • CRSP is downgraded to Equal Weight with a price target of $88.
  • RBC Capital notes that though SCD/BT filing remains on track for YE-22 in the EU, the Q2 release no longer cites US filing by YE-22, suggesting timing advantage vs. bluebird bio Inc (NASDAQ:BLUE) (still guiding 1Q23 filing) may have narrowed. 
  • Overall, RBC struggles with the commercial case for SCD and read Pfizer Inc's (NYSE:PFE) buyout of Global Blood Therapeutics Inc (NASDAQ:GBT) as indirect evidence that gene therapy/editing is unlikely to disrupt the market in the foreseeable future materially.
  • RBC has lowered the price target from $85 to $78, reiterating the Sector Perform rating.
  • Price Action: CRSP shares are down 6.32% at $76.25 during the market session on the last check Tuesday.
  • 巴克萊這麼説的CRISPR治療股份公司納斯達克(新浪納斯達克股票代碼：CRSP)22財年第二季度收益報告基本上是遞增的，突出了多個臨牀項目的進展，包括22年前提交SCD/BT中CTX001的在軌監管報告以及22年下半年提交1型糖尿病(T1D)VCTX211(下一代)的CTA報告的目標。
  • 儘管投資者關注的是CTX001的BLA提交，但分析師預計，即使有一些延遲，批准的可能性也很高。
  • 但鑑於同種異體CAR-T計劃的持久性以及未來12個月缺乏其他主要數據催化劑的問題，巴克萊已經採取了觀望態度。
  • CRSP評級下調至持平，目標價為88美元。
  • 加拿大皇家銀行資本指出，儘管SCD/BT申請仍在歐盟的YE-22的軌道上，但第二季度的新聞稿不再引用YE-22在美國的申請，這表明相對於藍鳥生物公司(納斯達克：BLUE)(仍在指導1Q23申請)的時機優勢可能已經縮小。
  • 總體而言，加拿大皇家銀行在SCD和Read的商業案例中舉步維艱輝瑞(紐約證券交易所股票代碼：PFE)收購全球血液治療公司(納斯達克：GBT)作為基因治療/編輯在可預見的未來不太可能實質性擾亂市場的間接證據。
  • 加拿大皇家銀行已將目標價從85美元下調至78美元，重申了行業表現評級。
  • 價格行動：CRSP股價週二尾盤下跌6.32%，至76.25美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論